{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:56:42Z","timestamp":1791176202287,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"vor","delay-in-days":643,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background. \u2003Human immunodeficiency virus (HIV) coinfection accelerates liver disease progression in individuals with chronic hepatitis C. We evaluated the associations of CD4, HIV RNA, and antiretroviral therapy (ART)-induced CD4 recovery with liver diagnoses in a prospective cohort of injecting drug users (IDUs).<\/jats:p><jats:p>Methods. \u2003We evaluated 383 coinfected IDUs in the Boston area, prospectively observed for a median of 1.8 years. Liver disease progression included the first occurrence of hepatocellular carcinoma, variceal bleeding, ascites, encephalopathy, or death due to hepatic failure. Multivariable-adjusted extended Cox models were specified to estimate hazard ratios (HRs) for comparisons of CD4, change in CD4 (from nadir), and HIV RNA with respect to liver disease progression events.<\/jats:p><jats:p>Results. \u2003Twenty-four persons experienced a liver disease progression event over 1155 person-years (2.1 per 100 person-years), including 20 deaths attributed to end-stage liver disease (1.7 per 100 person-years). CD4 at baseline and over follow-up strongly predicted liver disease progression (baseline CD4 &amp;lt;200 vs \u2265200: HR = 5.23, 95% confidence interval [CI], 2.30\u201311.92; time-updated CD4 &amp;lt;200 vs \u2265200: HR = 11.79, 95% CI, 4.47\u201331.07). Nadir CD4 was also a strong indicator (&amp;lt;100 vs \u2265100: HR = 3.52, 95% CI, 1.54\u20138.06). A lack of CD4 recovery (failure to increase 100 cells over nadir) among ART initiators was associated with increased risk (HR = 7.69; 95% CI, 2.60\u201322.69). Human immunodeficiency virus RNA was not significantly associated with liver disease progression.<\/jats:p><jats:p>Conclusions. \u2003Impaired immune function was highly predictive of liver disease progression in this cohort of IDUs, and a lack of CD4 recovery on ART was associated with increased risk of progression to HCV-associated liver disease.<\/jats:p>","DOI":"10.1093\/ofid\/ofv019","type":"journal-article","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T07:19:10Z","timestamp":1423207150000},"source":"Crossref","is-referenced-by-count":11,"title":["CD4 Recovery on Antiretroviral Therapy Is Associated With Decreased Progression to Liver Disease Among Hepatitis C Virus-Infected Injecting Drug Users"],"prefix":"10.1093","volume":"2","author":[{"given":"Jeffrey P.","family":"Anderson","sequence":"first","affiliation":[{"name":"Departments of Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"C. Robert","family":"Horsburgh","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Boston University School of Public Health"},{"name":"Sections of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige L.","family":"Williams","sequence":"additional","affiliation":[{"name":"Biostatistics, Harvard School of Public Health, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Tchetgen Tchetgen","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology"},{"name":"Biostatistics, Harvard School of Public Health, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nunes","sequence":"additional","affiliation":[{"name":"Gastroenterology, Boston Medical Center, Boston University School of Medicine, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cotton","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Boston University School of Public Health"},{"name":"Sections of Infectious Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George R.","family":"Seage","sequence":"additional","affiliation":[{"name":"Departments of Epidemiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,2,28]]},"reference":[{"key":"2020081006375592400_OFV019C1","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study","volume":"24","author":"Smith","year":"2010","journal-title":"AIDS"},{"key":"2020081006375592400_OFV019C2","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"2020081006375592400_OFV019C3","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/652283","article-title":"Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996\u20132006: collaborative analysis of 13 HIV cohort studies","volume":"50","author":"Antiretroviral Therapy Cohort Collaboration","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020081006375592400_OFV019C4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1086\/321909","article-title":"Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis","volume":"33","author":"Graham","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020081006375592400_OFV019C5","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/314720","article-title":"Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection","volume":"179","author":"Lesens","year":"1999","journal-title":"J Infect Dis"},{"key":"2020081006375592400_OFV019C6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-8278(97)80001-3","article-title":"Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis","volume":"26","author":"Soto","year":"1997","journal-title":"J Hepatol"},{"key":"2020081006375592400_OFV019C7","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","article-title":"Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group","volume":"34","author":"Sherman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020081006375592400_OFV019C8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"2020081006375592400_OFV019C9","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection","volume":"44","author":"Alter","year":"2006","journal-title":"J Hepatol"},{"key":"2020081006375592400_OFV019C10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2105\/AJPH.92.3.385","article-title":"Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities","volume":"92","author":"Murrill","year":"2002","journal-title":"Am J Public Health"},{"key":"2020081006375592400_OFV019C11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jama.288.2.199","article-title":"Hepatitis C and progression of HIV disease","volume":"288","author":"Sulkowski","year":"2002","journal-title":"JAMA"},{"key":"2020081006375592400_OFV019C12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"2020081006375592400_OFV019C13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/jhep.2001.29201","article-title":"The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study","volume":"34","author":"Di Martino","year":"2001","journal-title":"Hepatology"},{"key":"2020081006375592400_OFV019C14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/01.aids.0000198087.47454.e1","article-title":"Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease","volume":"20","author":"Merchante","year":"2006","journal-title":"AIDS"},{"key":"2020081006375592400_OFV019C15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.52.7.1035","article-title":"Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients","volume":"52","author":"Mohsen","year":"2003","journal-title":"Gut"},{"key":"2020081006375592400_OFV019C16","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/hep.21757","article-title":"Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy","volume":"46","author":"Pineda","year":"2007","journal-title":"Hepatology"},{"key":"2020081006375592400_OFV019C17","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/S0140-6736(03)14844-1","article-title":"Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection","volume":"362","author":"Qurishi","year":"2003","journal-title":"Lancet"},{"key":"2020081006375592400_OFV019C18","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1365-2893.2009.01197.x","article-title":"HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension","volume":"17","author":"Reiberger","year":"2010","journal-title":"J Viral Hepat"},{"key":"2020081006375592400_OFV019C19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1046\/j.1365-2893.2003.00413.x","article-title":"Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients","volume":"10","author":"Tural","year":"2003","journal-title":"J Viral Hepat"},{"key":"2020081006375592400_OFV019C20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1365-2893.2007.00874.x","article-title":"Documented rapid course of hepatic fibrosis between two biopsies in patients coinfected by HIV and HCV despite high CD4 cell count","volume":"14","author":"Bonnard","year":"2007","journal-title":"J Viral Hepat"},{"key":"2020081006375592400_OFV019C21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/135965350701200605","article-title":"Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study","volume":"12","author":"Giron-Gonzalez","year":"2007","journal-title":"Antivir Ther"},{"key":"2020081006375592400_OFV019C22","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1089\/apc.2007.0216","article-title":"Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C in Brazil","volume":"22","author":"Mendes-Correa","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"2020081006375592400_OFV019C23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/aid.2010.0168","article-title":"Immunological status does not influence hepatitis C virus or liver fibrosis in HIV-hepatitis C virus-coinfected patients","volume":"27","author":"Collazos","year":"2011","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020081006375592400_OFV019C24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/cid\/cit779","article-title":"Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans","volume":"58","author":"Anderson","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081006375592400_OFV019C25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.2012.7844","article-title":"Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV\/HCV","volume":"308","author":"Limketkai","year":"2012","journal-title":"JAMA"},{"key":"2020081006375592400_OFV019C26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3851\/IMP2419","article-title":"Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort","volume":"17","author":"Loko","year":"2012","journal-title":"Antivir Ther"},{"key":"2020081006375592400_OFV019C27","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","article-title":"Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study","volume":"356","author":"Greub","year":"2000","journal-title":"Lancet."},{"key":"2020081006375592400_OFV019C28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10096-003-1015-2","article-title":"Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naive patients coinfected with human immunodeficiency virus and hepatitis C virus","volume":"22","author":"Macias","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020081006375592400_OFV019C29","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1086\/430445","article-title":"Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals","volume":"40","author":"Antonucci","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020081006375592400_OFV019C30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s10096-006-0090-6","article-title":"Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment","volume":"25","author":"de Larranaga","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020081006375592400_OFV019C31","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/503569","article-title":"Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study","volume":"42","author":"Weis","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020081006375592400_OFV019C32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/592113","article-title":"CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy","volume":"47","author":"Khanna","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020081006375592400_OFV019C33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3851\/IMP1513","article-title":"Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy","volume":"15","author":"Castagna","year":"2010","journal-title":"Antivir Ther"},{"key":"2020081006375592400_OFV019C34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2893.2008.00970.x","article-title":"HCV\/HIV co-infection: time to re-evaluate the role of HIV in the liver?","volume":"15","author":"Blackard","year":"2008","journal-title":"J Viral Hepat"},{"key":"2020081006375592400_OFV019C35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy","volume":"44","author":"Brau","year":"2006","journal-title":"J Hepatol"},{"key":"2020081006375592400_OFV019C36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/135965350801300301","article-title":"Low current and nadir CD4+ T-cell counts are associated with higher hepatitis C virus RNA levels in the Swiss HIV cohort study","volume":"13","author":"Rauch","year":"2008","journal-title":"Antivir Ther"},{"key":"2020081006375592400_OFV019C37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ajg.2009.746","article-title":"Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection","volume":"105","author":"Nunes","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2020081006375592400_OFV019C38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1089\/apc.2010.0104","article-title":"Incidence and predictors of acute kidney injury in an urban cohort of subjects with HIV and hepatitis C virus coinfection","volume":"25","author":"Garg","year":"2011","journal-title":"AIDS Patient Care STDS"},{"key":"2020081006375592400_OFV019C39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"2020081006375592400_OFV019C40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1468-1293.2009.00701.x","article-title":"Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study","volume":"10","author":"Weber","year":"2009","journal-title":"HIV Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/1\/ofv019\/33620801\/ofv019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/2\/1\/ofv019\/33620801\/ofv019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T19:13:25Z","timestamp":1651173205000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofv019\/1463685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofv019","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015]]},"published":{"date-parts":[[2015,1,1]]},"article-number":"ofv019"}}